基于 DNA 超分子水凝胶的保护性 NK 细胞储库用于增强三阴性乳腺癌治疗
Protective NK Cell Reservoir Based on DNA Supramolecular Hydrogel for Enhanced Triple-Negative Breast Cancer Therapy.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
免疫检查点蛋白与乳腺癌新辅助化疗疗效的关系
英文原题：Relationship between immune checkpoint proteins and neoadjuvant chemotherapy response in breast cancer.
查看英文原题
Relationship between immune checkpoint proteins and neoadjuvant chemotherapy response in breast cancer.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
我们的研究提供了关于 ICP 与乳腺癌临床病理状态及 NAC 反应之间相关性的初步数据，并强调了进一步研究以确定其作为治疗靶点潜力的必要性。
研究思路结论见上方概要
背景
随着癌症免疫治疗的重大进展，针对免疫检查点蛋白（ICP）的治疗在乳腺癌中引起了关注，尽管研究多集中于转移性疾病患者以及对常规治疗无反应的患者。在此，我们旨在研究新辅助化疗给药前肿瘤间质和TIL（肿瘤浸润淋巴细胞）以及肿瘤组织中的ICP水平，以评估ICP水平、临床病理参数与NAC反应之间的关系。
方法
本研究纳入51例患者，在CD45+细胞中检测PD-1、PD-L1、CTLA-4、TIM-3、CD24和CD44水平，在CD45-细胞群中检测CD326、CD24、CD44和PD-L1蛋白表达水平。此外，评估肿瘤间质中CD44和CD24水平。根据TILS工作组标准检测TIL水平。NAC后的治疗反应根据MD Anderson RCB评分进行评估。
结果
我们的结果揭示了在高 TIL 水平的病例中 CTLA-4 与 CD44 表达之间呈正相关，以及在部分缓解病例中 TIL 水平与 CTLA-4 表达之间呈正相关。同样，在良好缓解病例中检测到 TIM3 与 PD-L1 水平之间呈正相关。此外，在部分完全缓解病例中，NAC 后的 TILs 与淋巴细胞中 PD-1/PD-L1 表达之间呈负相关。
展开英文摘要原文
MATERIALS AND METHODS
This study was conducted with 51 patients where PD-1, PD-L1, CTLA-4, TIM-3, CD24 and CD44 levels were investigated in CD45 + cells while CD326, CD24, CD44 and PD-L1 protein expression levels were investigated in CD45 - population. In addition, CD44 and CD24 levels were evaluated in the tumor stroma. TIL levels were investigated according to the TILS Working Group. Treatment responses after NAC were evaluated according to the MD Anderson RCB score.
RESULTS
Our results revealed positive correlation between CTLA-4 and CD44 expression in cases with high TIL levels as well as TIL levels and CTLA-4 expression in cases with partial response. Similarly, positive correlation was detected between TIM3 and PD-L1 levels in cases with good response. In addition, a negative correlation between TILs after NAC and PD-1/PD-L1 expression in lymphocytes in cases with partial complete response.
CONCLUSIONS
Our study provides preliminary data about the correlation between ICP and clinicopathological status and NAC response in breast cancer, in addition to underlining the requirement for further research to determine their potential as therapeutic targets.
论文信息
- 作者
- Kina Kilicaslan U、Aru B、Aydin Aksu S、Vardar Aker F、Yanikkaya Demirel G、Gurleyik MG
- 第一作者单位
- Department of General Surgery, Istanbul Haydarpasa Numune Training and Research Hospital, University of Health Sciences Turkey, İstanbul, Turkey.Turkey
- 通讯作者单位
- Department of General Surgery, Istanbul Haydarpasa Numune Training and Research Hospital, University of Health Sciences Turkey, İstanbul, Turkey. Electronic address: meryemgunay.gurleyik@sbu.edu.tr.Turkey
- 期刊
- Surgical oncology2024 Feb
- 原文标识
- PubMed 38290327 · DOI 10.1016/j.suronc.2024.102037